Most founders in healthcare chase predictable, smaller deals first. It feels safe, easy. But Shiv Rao, CEO of Abridge, a company now valued at $5.3 billion, says that approach is a trap. His counter-intuitive advice: you have to know when to pull your "yolo shot" and go for the big enterprise deals, or you'll miss your moment entirely.

Key Takeaways

  • Healthcare in the US isn't one giant market; it's a collection of many distinct, segmented markets, each needing a tailored approach.
  • A common founder mistake is staying "down market" too long, chasing smaller clients and missing the critical timing to pivot to large-scale enterprise deals.
  • Abridge's rapid scale to a $5.3 billion valuation came from perfectly timing an "up-market" push in 2023.
  • This strategic shift capitalized on a unique confluence of factors: widespread doctor and nurse burnout, financial pressures on health systems, and a readiness for AI tech.
  • Abridge had "pre-sold" the market, positioning themselves to capture demand when these macro conditions finally aligned.

The Trap of Staying "Down Market"

Shiv Rao is blunt: “Healthcare specifically in the United States, it's it's not one $5.3 trillion market. It's a bunch of different markets.” This segmentation is where many founders stumble. They get comfortable selling to smaller clinics or niche providers. The deals are simpler, sales cycles shorter, and initial traction feels good. But, according to Rao, this comfort becomes a cage.

“The trap that a lot of I think healthcare founders fall into is that they stay down market,” Rao says. “They don't figure out they don't like time their yolo shot to go up market at the right moment.” Staying small means you're playing in segments that don't allow for the kind of exponential growth that defines true enterprise value. You end up with a portfolio of scattered clients rather than the concentrated impact needed for scale, especially in a market as complex as healthcare.

Timing the "YOLO Shot" for Enterprise Scale

Abridge didn't shy away from this challenge. Instead, they waited. They played the long game, enduring a five-year period before their significant breakthrough. Then, in 2023, the stars aligned for their "yolo shot" – a direct push into large Integrated Delivery Networks (IDNs) and academic medical centers, where clinicians are concentrated and problems are most acute.

What made 2023 the moment? Rao points to a perfect storm of macro conditions. “On the other side of the pandemic, I'd say 40 50% of the doctors in this country were saying that they were burnt out... 30% of nurses in the country didn't want to be nurses in the next 12 months.” These pressures, combined with health systems facing immense financial strain and the concurrent rise of practical AI solutions, created an urgent demand for efficiency and relief. Abridge wasn't just lucky; they had done the groundwork. “We were pre-selling the market and preparing the market for what we could bring and then in 2023 when the sky opened we ran right in.”

This wasn't a cold launch. It was a calculated strike, pre-conditioned by years of market education and solution building. When the industry reached a breaking point, Abridge had a proven product and a primed market ready to adopt it at scale. Their ability to deliver value where clinicians were concentrated, and where pain points were most acute, drove their rapid ascent.

What to Do With This

Stop optimizing for incremental wins in smaller market segments. Instead, spend this week mapping your industry's "yolo shot" moment. Identify the macro shifts – regulatory changes, economic pressures, or workforce crises – that could create an urgent, widespread need for your solution among the largest players. Then, plan how you'll "pre-sell" those enterprise clients over the next 12-18 months, educating them on the problem and the future value you'll deliver, so you're ready to run in when the sky opens for you.